非侵襲性癌診断のグローバル市場(2022ー2031年):尿検査、画像検査、分光検査

• 英文タイトル:Non-invasive Cancer Diagnostics Market (Test Type: Urine Test, Imaging Test, and Spectroscopy) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031

Non-invasive Cancer Diagnostics Market (Test Type: Urine Test, Imaging Test, and Spectroscopy) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031「非侵襲性癌診断のグローバル市場(2022ー2031年):尿検査、画像検査、分光検査」(市場規模、市場予測)調査レポートです。• レポートコード:MRC2301F0075
• 出版社/出版日:Transparency Market Research / 2022年10月25日
• レポート形態:英文、PDF、160ページ
• 納品方法:Eメール
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥869,250 (USD5,795)▷ お問い合わせ
  Multi User¥1,319,250 (USD8,795)▷ お問い合わせ
  Corporate License¥1,769,250 (USD11,795)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
Transparency Market Research社では、世界の非侵襲性癌診断市場を調査対象とし、序論、仮定・調査手法、市場概要、主要インサイト、検査タイプ別分析(尿検査、画像検査、分光検査)、がん種別分析(乳がん、肺がん、血液がん、卵巣がん、その他)、エンドユーザー別分析(病院&診療所、外来診療、その他)、地域別分析(北米、ヨーロッパ、アジア太平洋、中南米、中東/アフリカ)、競争状況、企業情報などについて総合的に調査・分析をしました。なお、当書には、The University of Texas MD Anderson Cancer Center、Memorial Sloan Kettering Cancer Center、Dana-Farber Cancer Institute、Beverly Hills Cancer Center、SimonMed Imaging、RadNet Management, Inc.、RAYUS Radiology (Diagnostic Services Holdings, Inc.)、Unilabs AB、Sonic Healthcare Limited、Dr Lal PathLabs Ltd.などの主要企業情報が含まれています。
・序論
・仮定・調査手法
・市場概要
・主要インサイト

・世界の非侵襲性癌診断市場規模:検査タイプ別
- 尿検査の市場規模
- 画像検査の市場規模
- 分光検査の市場規模

・世界の非侵襲性癌診断市場規模:がん種別
- 乳がんの市場規模
- 肺がんの市場規模
- 血液がんの市場規模
- 卵巣がんの市場規模
- その他がん種の市場規模

・世界の非侵襲性癌診断市場規模:エンドユーザー別
- 病院&診療所における市場規模
- 外来診療における市場規模
- その他エンドユーザーにおける市場規模

・世界の非侵襲性癌診断市場規模:地域別
- 北米の非侵襲性癌診断市場規模
- ヨーロッパの非侵襲性癌診断市場規模
- アジア太平洋の非侵襲性癌診断市場規模
- 中南米の非侵襲性癌診断市場規模
- 中東/アフリカの非侵襲性癌診断市場規模

・競争状況
・企業情報

Non-Invasive Cancer Diagnostics Market – Scope of Report
TMR’s report on the global non-invasive cancer diagnostics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2022 to 2031. The report provides revenue of the global non-invasive cancer diagnostics market for the period 2017–2031, considering 2021 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global non-invasive cancer diagnostics market from 2022 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the non-invasive cancer diagnostics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global non-invasive cancer diagnostics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report sheds light on the changing competitive dynamics in the global non-invasive cancer diagnostics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global non-invasive cancer diagnostics market.

The report delves into the competitive landscape of the global non-invasive cancer diagnostics market. Key players operating in the global non-invasive cancer diagnostics market have been identified and each one of these has been profiled, in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are attributes of players in the global non-invasive cancer diagnostics market profiled in this report.

RESEARCH METHODOLOGY

The research methodology will be a combination of exhaustive primary and secondary research to analyze the market non-invasive cancer diagnostics.

Secondary Research

Secondary research includes a search of company literature, technical writing, patent data, Internet sources, and statistical data from government websites, trade associations, and agencies. This has proven to be the most reliable, effective, and successful approach for obtaining precise data, capturing industry participants’ insights, and recognizing business opportunities.

Secondary research sources that we typically refer, but are not limited to:

Company websites, presentations, annual reports, white papers, technical paper, product brochure
Internal and external proprietary databases and relevant patents
National government documents, statistical databases, and market reports
News articles, press releases, and webcasts specific to companies operating in the market

Specific Secondary Sources:

Industry Sources:
WorldWideScience.org
Elsevier, Inc.
National Institutes of Health (NIH)
PubMed
NCBI
Department of Health Care Service
Trade Data Sources
Trade Map
UN Comtrade
Trade Atlas
Company Information
OneSource Business Browser
Hoover’s
Factiva
Bloomberg
Mergers & Acquisitions
Thomson Mergers & Acquisitions
MergerStat
Profound

Primary Research

During the course of research, we conduct in-depth interviews and discussions with a wide range of key industry participants and opinion leaders. Primary research represents bulk of research efforts, supplemented by extensive secondary research.

We conduct primary interviews on the ongoing basis with industry participants and commentators to validate data and analysis. A typical research interview fulfills the following functions:

Provides first-hand information on market size, market trends, growth trends, competitive landscape, outlook, etc.
Helps in validating and strengthening secondary research findings
Further develops the analysis team’s expertise and market understanding
Primary research involves e-mail interactions, telephonic interviews, as well as face-to-face interviews for each market, category, segment, and sub-segment across geographies

Participants who typically take part in such a process include, but are not limited to:

Industry participants: Marketing/product managers, market intelligence managers, and regional sales managers
Purchasing/Sourcing managers, technical personnel, distributors
Outside experts: Investment bankers, valuation experts, and research analysts specializing in specific markets
Key opinion leaders specializing in different areas corresponding to different industry verticals

List of primary participants, but not limited to:

Advanced Oncotherapy PLC
Danfysik A/S
Hitachi, Ltd.
IBA Worldwide
Mevion Medical Systems, Inc.

Data Triangulation: Information culled from “Secondary & Primary Sources” is cross-checked with “TMR Knowledge Repository”, which is updated every quarter.

Market Estimation: Market size estimations involved in-depth study of product features, technology updates, geographic presence, product demand, sales data (value or volume), historical year-on-year growth, and others. Other approaches were also utilized to derive market size and forecasts. Where no hard data was available, we employed modeling techniques in order to produce comprehensive datasets. A rigorous methodology has been adopted, wherein the available hard data are cross-referenced with the following data types to produce estimates:

Demographic Data: Healthcare expenditure, inflation rates, and others
Industry Indicators: R&D investment, technology stage, and infrastructure, sector growth, and facilities

Market Forecasting: Market forecasts for various segments are derived taking into account drivers, restraints/challenges, and opportunities prevailing in the market and considering advantages/disadvantages of segments/sub-segments over other segments/sub-segments. Business environment, historical sales pattern, unmet needs, competitive intensity, and country-wise surgery data are some of the other pivotal factors, which are considered to derive market forecasts.

レポート目次

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Non-invasive Cancer Diagnostics Market
4. Market Overview
4.1. Overview
4.2. Market Dynamics
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.3. Global Non-invasive Cancer Diagnostics Market Value Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Technological Advancements
5.2. Disease Prevalence & Incidence Rate Globally With Key Countries
5.3. COVID-19 Pandemic Impact on Industry (value chain and short/mid/long term impact)
6. Global Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Test Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Test Type, 2017–2031
6.3.1. Urine Test
6.3.2. Imaging Test
6.3.2.1. Computerized Tomography
6.3.2.2. Magnetic Resonance Imaging
6.3.2.3. Nuclear Medicine Scans
6.3.2.4. X-ray/Mammography
6.3.2.5. Ultrasound
6.3.3. Spectroscopy
6.4. Market Attractiveness Analysis, by Test Type
7. Global Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Cancer Type
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Cancer Type, 2017–2031
7.3.1. Breast Cancer
7.3.2. Lung Cancer
7.3.3. Blood Cancer
7.3.4. Ovarian Cancer
7.3.5. Colorectal Cancer
7.3.6. Others
7.4. Market Attractiveness Analysis, by Cancer Type
8. Global Non-invasive Cancer Diagnostics Market Analysis and Forecast, by End-user
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by End-user, 2017–2031
8.3.1. Hospitals & Clinics
8.3.2. Ambulatory Care
8.3.3. Others
8.4. Market Attractiveness Analysis, by End-user
9. Global Non-invasive Cancer Diagnostics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Non-invasive Cancer Diagnostics Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Test Type, 2017–2031
10.2.1. Urine Test
10.2.2. Imaging Test
10.2.2.1. Computerized Tomography
10.2.2.2. Magnetic Resonance Imaging
10.2.2.3. Nuclear Medicine Scans
10.2.2.4. X-ray/Mammography
10.2.2.5. Ultrasound
10.2.3. Spectroscopy
10.3. Market Value Forecast, by Cancer Type, 2017–2031
10.3.1. Breast Cancer
10.3.2. Lung Cancer
10.3.3. Blood Cancer
10.3.4. Ovarian Cancer
10.3.5. Colorectal Cancer
10.3.6. Others
10.4. Market Value Forecast, by End-user, 2017–2031
10.4.1. Hospitals & Clinics
10.4.2. Ambulatory Care
10.4.3. Others
10.5. Market Value Forecast, by Country, 2017–2031
10.5.1. U.S.
10.5.2. Canada
10.6. Market Attractiveness Analysis
10.6.1. By Test Type
10.6.2. By Cancer Type
10.6.3. By End-user
10.6.4. By Country
11. Europe Non-invasive Cancer Diagnostics Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Test Type, 2017–2031
11.2.1. Urine Test
11.2.2. Imaging Test
11.2.2.1. Computerized Tomography
11.2.2.2. Magnetic Resonance Imaging
11.2.2.3. Nuclear Medicine Scans
11.2.2.4. X-ray/Mammography
11.2.2.5. Ultrasound
11.2.3. Spectroscopy
11.3. Market Value Forecast, by Cancer Type, 2017–2031
11.3.1. Breast Cancer
11.3.2. Lung Cancer
11.3.3. Blood Cancer
11.3.4. Ovarian Cancer
11.3.5. Colorectal Cancer
11.3.6. Others
11.4. Market Value Forecast, by End-user, 2017–2031
11.4.1. Hospitals & Clinics
11.4.2. Ambulatory Care
11.4.3. Others
11.5. Market Value Forecast, by Country/Sub-region, 2017–2031
11.5.1. Germany
11.5.2. U.K.
11.5.3. France
11.5.4. Italy
11.5.5. Spain
11.5.6. Rest of Europe
11.6. Market Attractiveness Analysis
11.6.1. By Test Type
11.6.2. By Cancer Type
11.6.3. By End-user
11.6.4. By Country/Sub-region
12. Asia Pacific Non-invasive Cancer Diagnostics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Test Type, 2017–2031
12.2.1. Urine Test
12.2.2. Imaging Test
12.2.2.1. Computerized Tomography
12.2.2.2. Magnetic Resonance Imaging
12.2.2.3. Nuclear Medicine Scans
12.2.2.4. X-ray/Mammography
12.2.2.5. Ultrasound
12.2.3. Spectroscopy
12.3. Market Value Forecast, by Cancer Type, 2017–2031
12.3.1. Breast Cancer
12.3.2. Lung Cancer
12.3.3. Blood Cancer
12.3.4. Ovarian Cancer
12.3.5. Colorectal Cancer
12.3.6. Others
12.4. Market Value Forecast, by End-user, 2017–2031
12.4.1. Hospitals & Clinics
12.4.2. Ambulatory Care
12.4.3. Others
12.5. Market Value Forecast, by Country/Sub-region, 2017–2031
12.5.1. China
12.5.2. Japan
12.5.3. India
12.5.4. Australia & New Zealand
12.5.5. Rest of Asia Pacific
12.6. Market Attractiveness Analysis
12.6.1. By Test Type
12.6.2. By Cancer Type
12.6.3. By End-user
12.6.4. By Country/Sub-region
13. Latin America Non-invasive Cancer Diagnostics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Test Type, 2017–2031
13.2.1. Urine Test
13.2.2. Imaging Test
13.2.2.1. Computerized Tomography
13.2.2.2. Magnetic Resonance Imaging
13.2.2.3. Nuclear Medicine Scans
13.2.2.4. X-ray/Mammography
13.2.2.5. Ultrasound
13.2.3. Spectroscopy
13.3. Market Value Forecast, by Cancer Type, 2017–2031
13.3.1. Breast Cancer
13.3.2. Lung Cancer
13.3.3. Blood Cancer
13.3.4. Ovarian Cancer
13.3.5. Colorectal Cancer
13.3.6. Others
13.4. Market Value Forecast, by End-user, 2017–2031
13.4.1. Hospitals & Clinics
13.4.2. Ambulatory Care
13.4.3. Others
13.5. Market Value Forecast, by Country/Sub-region, 2017–2031
13.5.1. Brazil
13.5.2. Mexico
13.5.3. Rest of Latin America
13.6. Market Attractiveness Analysis
13.6.1. By Test Type
13.6.2. By Cancer Type
13.6.3. By End-user
13.6.4. By Country/Sub-region
14. Middle East & Africa Non-invasive Cancer Diagnostics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Test Type, 2017–2031
14.2.1. Urine Test
14.2.2. Imaging Test
14.2.2.1. Computerized Tomography
14.2.2.2. Magnetic Resonance Imaging
14.2.2.3. Nuclear Medicine Scans
14.2.2.4. X-ray/Mammography
14.2.2.5. Ultrasound
14.2.3. Spectroscopy
14.3. Market Value Forecast, by Cancer Type, 2017–2031
14.3.1. Breast Cancer
14.3.2. Lung Cancer
14.3.3. Blood Cancer
14.3.4. Ovarian Cancer
14.3.5. Colorectal Cancer
14.3.6. Others
14.4. Market Value Forecast, by End-user, 2017–2031
14.4.1. Hospitals & Clinics
14.4.2. Ambulatory Care
14.4.3. Others
14.5. Market Value Forecast, by Country/Sub-region, 2017–2031
14.5.1. GCC Countries
14.5.2. South Africa
14.5.3. Rest of Middle East & Africa
14.6. Market Attractiveness Analysis
14.6.1. By Test Type
14.6.2. By Cancer Type
14.6.3. By End-user
14.6.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player – Competition Matrix (by tier and size of companies)
15.2. Company Profiles
15.2.1. The University of Texas MD Anderson Cancer Center
15.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.1.2. Company Financials
15.2.1.3. Growth Strategies
15.2.1.4. SWOT Analysis
15.2.2. Memorial Sloan Kettering Cancer Center
15.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.2.2. Company Financials
15.2.2.3. Growth Strategies
15.2.2.4. SWOT Analysis
15.2.3. Dana-Farber Cancer Institute
15.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.3.2. Company Financials
15.2.3.3. Growth Strategies
15.2.3.4. SWOT Analysis
15.2.4. Beverly Hills Cancer Center
15.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.4.2. Company Financials
15.2.4.3. Growth Strategies
15.2.4.4. SWOT Analysis
15.2.5. SimonMed Imaging
15.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.5.2. Company Financials
15.2.5.3. Growth Strategies
15.2.5.4. SWOT Analysis
15.2.6. RadNet Management, Inc.
15.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.6.2. Company Financials
15.2.6.3. Growth Strategies
15.2.6.4. SWOT Analysis
15.2.7. RAYUS Radiology (Diagnostic Services Holdings, Inc.)
15.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.7.2. Company Financials
15.2.7.3. Growth Strategies
15.2.7.4. SWOT Analysis
15.2.8. Unilabs AB
15.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.8.2. Company Financials
15.2.8.3. Growth Strategies
15.2.8.4. SWOT Analysis
15.2.9. Sonic Healthcare Limited
15.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.9.2. Company Financials
15.2.9.3. Growth Strategies
15.2.9.4. SWOT Analysis
15.2.10. Dr Lal PathLabs Ltd.
15.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
15.2.10.2. Company Financials
15.2.10.3. Growth Strategies
15.2.10.4. SWOT Analysis

List of Tables

Table 01: Global Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

Table 02: Global Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2031

Table 03: Global Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 04: Global Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 05: North America Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

Table 06: North America Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2031

Table 07: North America Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 08: North America Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 09: Europe Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

Table 10: Europe Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2031

Table 11: Europe Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 12: Europe Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 13: Asia Pacific Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

Table 14: Asia Pacific Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2031

Table 15: Asia Pacific Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 16: Asia Pacific Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 17: Latin America Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

Table 18: Latin America Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2031

Table 19: Latin America Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 20: Latin America Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 21: Middle East & Africa Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Test Type, 2017–2031

Table 22: Middle East & Africa Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Cancer Type, 2017–2031

Table 23: Middle East & Africa Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by End-user, 2017–2031

Table 24: Middle East & Africa Non-invasive Cancer Diagnostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031


• 英文レポート名:Non-invasive Cancer Diagnostics Market (Test Type: Urine Test, Imaging Test, and Spectroscopy) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022-2031
• 日本語訳:非侵襲性癌診断のグローバル市場(2022ー2031年):尿検査、画像検査、分光検査
• レポートコード:MRC2301F0075お問い合わせ(見積依頼・ご注文・質問)